1. Medtech Insight
  2. >>Business
  3. >>Deals

ReWalk Robotics’ Planned Acquisition Of Anti-Gravity Maker AlterG For $19M Paves Way To Profitability

The company could achieve positive profitability as early as 2025, according to H.C. Wainwright & Co analyst Swayampakula Ramakanth.

 
• By Marion Webb

ReWalk Robotics’ planned $19m acquisition of AlterG will put ReWalk on the path to profitability and positive cash flow, creating a combined company with trailing 12-month revenues of about $26m.

Paralympian
• Source: Shutterstock

ReWalk Robotics Ltd.’ announced plans to acquire AlterG, a provider of anti-gravity systems for physical and neurological rehabilitation, is expected to put it on solid grounds to expand its portfolio and achieve profitability. The $19m deal is expected to close 11 August.

AlterG uses NASA-derived differential air pressure technology to reduce gravitational load and body weight, which enables patients and

Key Takeaways

  • ReWalk Robotics’ planned $19m acquisition of AlterG will put ReWalk on the path to profitability and positive cash flow, creating a combined company with trailing 12-month revenues about $26m.

  • AlterG, which uses NASA-derived differential air-pressure technology to reduce gravitational load and body weight, enabling patients and athletes to move unrestricted and pain-free, achieved $20m in 2022 revenues, has more than 4,000 installed users, and distribution partnerships in over 40 countries

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 
• By Malcolm Spicer

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 
• By Natasha Barrow

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

Careology And Entia Partner To ‘Enhance’ Remote Monitoring For Patients With Cancer

 
• By Natasha Barrow

Careology and Entia are partnering to “alleviate the burden of routine patient assessments” on people with cancer. The two early-stage London-based health tech startups already provide services to UK National Health Service (NHS) patients.

More from Business

Synchron And Apple Team Up To Use ‘Mind-Thought Connection’ To Control iPhones, iPads

 
• By Marion Webb

Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Danaher Faces $350M Tariff Hit, But Says It’s Ready To Absorb The Blow

 
• By Shubham Singh

Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.